Zeljko Prijovic

Dr. Zeljko Prijovic

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2022 in Nanotechnology
Verified
Journal Article
Closed access
AVAleksandar Vukadinović
Aleksandar Vukadinović
ZMZorana Milanović
Zorana Milanović
Miloš OgnjanovićMiloš Ognjanović
Miloš Ognjanović
DJDrina Janković
Drina Janković
MRMagdalena Radović
Magdalena Radović
ZPZeljko Prijovic
Zeljko Prijovic
Radiolabelled superparamagnetic iron oxide nanoparticles (SPIONs) are a promising nanomaterial for the development of dual radiation/hyperthermia cancer therapy. To that purpose, flower-shaped SPIONs with an exceptional heating capability were synthesised and coated with citrate, dextran or (3-aminopropyl)triethoxysilane. Both non-coated and coated SPIONs were nontoxic to CT-26 mouse colon cancer cells up to 1.0 mg ml −1 in vitro . In an oscillating magnetic field, citrate-coated SPIONs (CA/SPIONs) displayed the highest heating rate ( SAR ∼ 253 W g −1 ) and the strongest hyperthermia effects against CT-26 cells. Labelling of the CA/SPIONs by the 90 Y radionuclide, emitting β − radiation with an average/maximum energy of 0.94/2.23 MeV, and deep tissue penetration generated 90 Y-CA/SPIONs intended for the therapy of solid tumours. However, intravenous injection of 90 Y-CA/SPIONs in CT-26 xenograft-bearing mice resulted in low tumour accumulation. On the contrary, intratumoural injection resulted in long-term retention at the injection site. A single intratumoural injection of 0.25 mg CA/SPIONs followed by 30-min courses of magnetic hyperthermia for four consecutive days caused a moderate antitumour effect against CT-26 and 4T1 mouse tumour xenografts. Intratumoural application of 1.85 MBq/0.25 mg 90 Y-CA/SPIONs, alone or combined with hyperthermia, caused a significant ( P ≤ 0.01) antitumour effect without signs of systemic toxicity. The results confirm the suitability of 90 Y-CA/SPIONs for monotherapy or dual magnetic hyperthermia-radionuclide nanobrachytherapy (NBT) of solid tumours.

13 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DSDragana Stankovic
Dragana Stankovic
MRMagdalena Radovic
Magdalena Radovic
ASAljoša Stanković
Aljoša Stanković
MMMarija Mirković
Marija Mirković
AVAleksandar Vukadinovic
Aleksandar Vukadinovic
ZPZeljko Prijovic
Zeljko Prijovic
As an alternative to classical brachytherapy, intratumoral injection of radionuclide-labeled nanoparticles (nanobrachytherapy, NBT) has been investigated as a superior delivery method over an intravenous route for radionuclide therapy of solid tumors. We created superparamagnetic iron oxide nanoparticles (SPIONs) coated with meso-1,2-dimercaptosuccinic acid (DMSA) and radiolabeled with Lutetium-177 (177Lu), generating 177Lu-DMSA@SPIONs as a potential antitumor agent for nanobrachytherapy. Efficient radiolabeling of DMSA@SPIONS by 177Lu resulted in a stable bond with minimal leakage in vitro. After an intratumoral injection to mouse colorectal CT-26 or breast 4T1 subcutaneous tumors, the nanoparticles remained well localized at the injection site for weeks, with limited leakage. The dose of 3.70 MBq/100 µg/50 µL of 177Lu-DMSA@SPIONs applied intratumorally resulted in a high therapeutic efficacy, without signs of general toxicity. A decreased dose of 1.85 MBq/100 µg/50 µL still retained therapeutic efficacy, while an increased dose of 9.25 MBq/100 µg/50 µL did not significantly benefit the therapy. Histopathology analysis revealed that the 177Lu-DMSA@SPIONs act within a limited range around the injection site, which explains the good therapeutic efficacy achieved by a single administration of a relatively low dose without the need for increased or repeated dosing. Overall, 177Lu-DMSA@SPIONs are safe and potent agents suitable for intra-tumoral administration for localized tumor radionuclide therapy.

27 January 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AVAleksandar Vukadinovic
Aleksandar Vukadinovic
Miloš OgnjanovićMiloš Ognjanović
Miloš Ognjanović
MMMilica Mijović
Milica Mijović
BWBryce Warren
Bryce Warren
SESlavica Milorad Eric
Slavica Milorad Eric
ZPZeljko Prijovic
Zeljko Prijovic
Background: The rapid rise in cancer incidence significantly augments efforts to improve cancer treatments. A multimodal approach in the nanobrachytherapy of solid tumors is one of the promising methods under investigation. This study presents a novel biocompatible lignin-based nanomaterial, loaded with cytostatic agent SN-38 and radionuclide 131I, for simultaneous radiation and chemotherapy of solid tumors by a nanobrachytherapy approach. Method: Nanoparticles of ~100 nm in size, composed of lignin alone or loaded with 10% (m/m) of SN-38 (SN-38@lignin), were synthesized using a bottom-up approach and characterized. Subsequent radiolabeling of the nanoparticles by 131I produced 131I-lignin and 131I-SN-38@lignin. Their antitumor efficiency was tested against luciferase-expressing 4T1 mouse breast cancer xenografts of ~100 mm3 size on Balb/c mice. Results: An intratumoral injection of 1.85 MBq of 131I-lignin was retained within the tumor and achieved a moderate twofold decrease in tumor size compared to the control group. Injecting SN-38@lignin containing 25 µg of SN-38 decreased tumor size 3.5-fold. The therapy using the same doses of 131I-SN-38@lignin produced the most potent antitumor effect, with tumors being 6-fold smaller and having extensive intratumoral necrosis, all of it without signs of systemic toxicity. Conclusions: These results support the intratumoral delivery of lignin-based nanomaterial carrying radioisotopes and camptothecins for effective multimodal anticancer therapy.

1 January 2024
Verified
Conference Paper
Closed access
DSDragana Stankovic
Dragana Stankovic
MRMagdalena Radovic
Magdalena Radovic
MMMarija Mirković
Marija Mirković
ZMZorana Milanovic
Zorana Milanovic
ASAljoša Stanković
Aljoša Stanković
ZPZeljko Prijovic
Zeljko Prijovic
Combined radionuclide therapy with magnetic nanoparticles has been a research focus as a promising approach for tumor therapy. In this study, superparamagnetic iron oxide nanoparticles (SPIONs) were synthesized using the co-precipitation method and coated with meso-1,2- dimercaptosuccinic acid (DMSA). Structural investigations showed that DMSA-coated SPIONs had a particle size of 140.3±6.5 nm in diameter with a spherical morphology. With a zeta potential of −35.1 mV, functionalization with DMSA led to increase the stability of the nanoparticles in solution. DMSA-SPIONs were radiolabeled with 177Lu in high radiolabeling yield (86.6 ± 2.1%, and after separation by magnetic decantation >99%), showing high in vitro stability in saline and human serum up to 96 h. After intratumoral injection into mouse colorectal CT-26 or breast 4T1 subcutaneous tumors, the radiolabeled nanoparticles remained well localized at the injection site over a 14-day period, with limited leakage.